Inclusion Criteria:

- Written informed consent

- Subjects with: non-Hodgkin's lymphoma, Hodgkin's disease, acute myelogenous leukemia,
acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic
leukemia, or multiple myeloma

- Minimum of 1.5 x 10^6 CD34+ cells/kg cryopreserved and to be transplanted.

Exclusion Criteria:

- Cancer other than those specified in inclusion criteria above (except: adequately
treated basal cell carcinoma of the skin)

- Prior bone marrow or peripheral blood stem cell transplantation - Negatively selected
(purged) stem cell product - Current active infection or oral mucositis

- Congestive heart failure as defined by New York Heart Association class III or IV.

- History of or current diagnosis of pancreatitis

- Inadequate renal function (serum creatinine greater than 1.5x the upper limit of
normal per the institutional guidelines)

- Inadequate liver function (direct bilirubin greater than 1.5x the upper limit of
normal, AST greater than 3x upper limit of normal and/or ALT greater than 3x upper
limit of normal per the institutional guidelines)

- Inadequate pulmonary function as measured by a corrected DLCO less than 50% of
predicted.

- Subject is currently enrolled in or has not yet completed at least 30 days since
ending other investigational device or drug trial(s), or subject is receiving other
investigational agent(s)